文献速递神经免疫

血清神经丝轻链水平与多发性硬化患者12年长期病程的关联

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years.
PubMed 文献 · JAMA Neurol · 2019-01-01

这项单中心前瞻性观察队列研究纳入607例多发性硬化患者,随访中位10年,发现基线血清神经丝轻链(sNFL)与EDSS评分、MS亚型及治疗状态相关,并与10年脑容量萎缩显著关联,但sNFL对复发活动和长期残疾进展的预测能力有限。

要点

  • 基线sNFL与EDSS评分、MS亚型及治疗状态显著相关。
  • 基线sNFL单独解释10年脑萎缩方差的约11.6%,多变量分析中为18.0%。
  • 高效治疗5年后sNFL水平较平台治疗和未治疗者降低更明显。

核心结论

  • sNFL与MS临床和神经影像结局存在显著关联,支持其作为疾病活动度的客观替代指标。
  • 在早期治疗的患者数据集中,sNFL对复发活动和长期残疾进展的预测能力有限。

研究设计与样本

  • 单中心、进行中的前瞻性观察队列研究,纳入加州大学旧金山分校EPIC研究607例MS患者,2004年7月1日至2017年8月31日。
  • 每年临床评估和样本采集持续5年,之后至多12年不同时间点采集,中位随访10年(IQR 7-11)。
  • 采用敏感单分子阵列平台检测sNFL,并与临床和MRI变量进行单变量和多变量分析。

主要发现

  • 基线sNFL与EDSS评分显著相关(β=1.080;95%CI 1.047-1.114;P<.001)。
  • 基线sNFL与MS亚型显著相关(β=1.478;95%CI 1.279-1.707;P<.001)。
  • 基线sNFL与治疗状态显著相关(β=1.120;95%CI 1.007-1.245;P=.04)。
  • EDSS恶化与sNFL随时间变化存在显著交互作用(β=1.015;95%CI 1.007-1.023;P<.001)。
  • 随访5年后,高效治疗较未治疗者sNFL水平更低(β=0.946;95%CI 0.915-0.976;P<.001),较平台治疗者亦更低(β=0.972;95%CI 0.948-0.998;P=.04)。

关键数值与推荐

  • 基线sNFL单独解释10年脑容量萎缩方差的约11.6%。
  • 考虑性别、年龄和病程的多变量分析中,基线sNFL解释10年脑容量萎缩方差的18.0%。
  • 3911份序贯采集样本中3904份通过质量控制用于sNFL定量。

临床怎么用

  • sNFL可作为MS疾病活动度的客观替代指标辅助监测。
  • 在已接受早期治疗的患者中,不应仅依赖sNFL预测复发或长期残疾进展。
  • 高效治疗与sNFL水平降低相关,可作为治疗反应的参考指标之一。

局限性

  • 单中心研究,所有参与者均为非西班牙裔欧洲裔,结果外推需谨慎。
  • sNFL对个体患者决策的效用尚需进一步前瞻性研究评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Blood sample-based biomarkers that are associated with clinically meaningful outcomes for patients with multiple sclerosis (MS) have not been developed. OBJECTIVE: To evaluate the potential of serum neurofilament light chain (sNFL) measurements as a biomarker of disease activity and progression in a longitudinal MS data set. DESIGN, SETTING, AND PARTICIPANTS: Single-center, ongoing, prospective observational cohort study of 607 patients with MS from the longitudinal EPIC (Expression, Proteomics, Imaging, Clinical) study at the University of California, San Francisco from July 1, 2004, through August 31, 2017. Clinical evaluations and sample collection were performed annually for 5 years, then at different time points for up to 12 years, with a median follow-up duration of 10 (interquartile range, 7-11) years. Serum NFL levels were measured using a sensitive single molecule array platform and compared with clinical and magnetic resonance imaging variables with the use of univariable and multivariable analyses. MAIN OUTCOMES AND MEASURES: The main outcomes were disability progression defined as clinically significant worsening on the Expanded Disability Status Scale (EDSS) score and brain fraction atrophy. RESULTS: Mean (SD) age of the 607 study participants at study entry was 42.5 (9.8) years; 423 (69.7%) were women; and all participants were of non-Hispanic European descent. Of 3911 samples sequentially collected, 3904 passed quality control for quantification of sNFL. Baseline sNFL levels showed significant associations with EDSS score (β, 1.080; 95% CI, 1.047-1.114; P < .001), MS subtype (β, 1.478; 95% CI, 1.279-1.707; P < .001), and treatment status (β, 1.120; 95% CI, 1.007-1.245; P = .04). A significant interaction between EDSS worsening and change in levels of sNFL over time was found (β, 1.015; 95% CI, 1.007-1.023; P < .001). Baseline sNFL levels alone were associated with approximately 11.6% of the variance in brain fraction atrophy at year 10. In a multivariable analysis that considered sex, age, and disease duration, baseline sNFL levels were associated with 18.0% of the variance in brain fraction atrophy at year 10. After 5 years' follow-up, active treatment was associated with lower levels of sNFL, with high-potency treatments associated with the greater decreases in sNFL levels compared with platform therapies (high-potency vs untreated: β, 0.946; 95% CI, 0.915-0.976; P < .001; high-potency vs platform: β, 0.972; 95% CI, 0.948-0.998; P = .04). CONCLUSIONS AND RELEVANCE: This study found that statistically significant associations of sNFL with relevant clinical and neuroimaging outcomes in MS were confirmed and extended, supporting the potential of sNFL as an objective surrogate of ongoing MS disease activity. In this data set of patients with MS who received early treatment, the prognostic power of sNFL for relapse activity and long-term disability progression was limited. Further prospective studies are necessary to assess the assay's utility for decision-making in individual patients.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cantó E, Barro C, Zhao C, et al. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurol. 2019. PMID: 31403661. doi:10.1001/jamaneurol.2019.2137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。